UK HRA to review 'confusing' drug trial registration requirements
This article was originally published in SRA
Executive Summary
The UK Health Research Authority is to review its requirements for the registration of clinical trials of drugs after a judge ruled that while it was appropriate for the HRA to take account of both legal and ethical obligations in its work, the wording of some of the material on its website regarding the obligation to register Phase I studies was "defective" and "confusing"1,2.